B.Riley Reiterates Buy Rating on Capricor Therapeutics (CAPR)

May 13, 2026 4:15 AM

B.Riley analyst Madison El-Saadi reiterated a Buy rating and $63.00 price target on Capricor Therapeutics (NASDAQ: CAPR).The analyst comments "We're ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found